Previous Pause Next
Home >> News Center >>
Clinical Trials
Analyses Find Type 2 Diabetes Patients Treated With BYDUREON™ Experienced Reduction In Cardiovascular Risk Factors: Results Presented At EASD 20 PDF Print E-mail
Tuesday, 13 September 2011 00:53
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON™ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments.
Read more...
 
ImmunoCellular Therapeutics Announces 55% Overall Survival at Three years from Phase I Study in Glioblastoma PDF Print E-mail
Monday, 12 September 2011 17:59

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

Read more...
 
Histogenics Appoints Industry Veterans to Support NeoCart® Phase 3 Clinical Development PDF Print E-mail
Monday, 12 September 2011 17:57

Histogenics Corporation, a privately held regenerative medicine company, has appointed Michael Lewis, M.D., as Chief Medical Officer and Peter Hamilton as Vice President of Manufacturing and Production.

Read more...
 
NOVAVAX Announces Publication of Results From H5N1 Influenza Virus-Like Particle Vaccine Phase I/IIa Clinical Trial PDF Print E-mail
Saturday, 10 September 2011 00:31
Novavax, Inc. (Nasdaq:NVAX) announced today the publication of an article that reported new safety, immunogenicity and cross-reactivity results from a Phase I/IIa clinical study of the company's H5N1 influenza virus-like particle (VLP) vaccine candidate that was conducted in 2008.
Read more...
 
Metabolic Solutions Development Company Reports Positive Top-Line Results From Phase 2a Study Of Its Second Compound To Treat Type 2 Diabetes PDF Print E-mail
Saturday, 10 September 2011 00:06
Metabolic Solutions Development Company, LLC (MSDC) confirmed today the potential of MSDC-0602 to achieve significant glucose control in type 2 diabetes patients and increase insulin sensitivity based on preliminary analysis from its Phase 2a trial of MSDC-0602, a novel insulin sensitizer.
Read more...
 
TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes PDF Print E-mail
Friday, 09 September 2011 00:52
TWi Biotechnology, Inc. announces the successful patient recruitment for the multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.
Read more...
 
Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad PDF Print E-mail
Friday, 09 September 2011 00:50
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.
Read more...
 
Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 PDF Print E-mail
Thursday, 08 September 2011 16:37

Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the initiation of a Phase I clinical trial of the Company's lead drug candidate ME-143 in patients with refractory solid tumors.

Read more...
 
BHR Pharma Meets Critical Enrollment Milestone For Its SyNAPSe® Clinical Trial PDF Print E-mail
Thursday, 08 September 2011 16:33

BHR Pharma, LLC (BHR) has now enrolled 200 patients in the SyNAPSe® Phase 3 clinical trial of progesterone for traumatic brain injury (TBI).

Read more...
 
Furiex Reports Positive Phase II Results for MuDelta in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome PDF Print E-mail
Wednesday, 07 September 2011 01:42

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced successful results from its Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Read more...
 
Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE PDF Print E-mail
Monday, 12 September 2011 18:00
Delcath Systems, Inc. announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress held this week in Munich, Germany.
Read more...
 
Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Cancer Presented In Oral Session At The ASCO 2011 Symposium PDF Print E-mail
Monday, 12 September 2011 17:58
Nektar Therapeutics (Nasdaq: NKTR) announced that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.
Read more...
 
Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology PDF Print E-mail
Monday, 12 September 2011 17:56
Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced that an article entitled "Pivotal Trial with Plant-Cell-Expressed Recombinant Glucocerebrosidase, taliglucerase alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease" has been published in Blood, the Journal of the American Society of Hematology.
Read more...
 
Roche Starts Early Stage Clinical Trial in Down Syndrome PDF Print E-mail
Saturday, 10 September 2011 00:16
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.
Read more...
 
Long-Term Survival For Inoperable Stage III Lung Cancer Improved By Concurrent Chemo And Radiation Therapy PDF Print E-mail
Saturday, 10 September 2011 00:04
Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option.
Read more...
 
ImmunoCellular Therapeutics gives Site Update for Phase II trial of ICT-107 PDF Print E-mail
Friday, 09 September 2011 00:51

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company’s dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

Read more...
 
Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain PDF Print E-mail
Friday, 09 September 2011 00:49
Nektar Therapeutics (Nasdaq: NKTR) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181, the company's novel opioid analgesic drug candidate.
Read more...
 
Initial Trial of Sanaria's Malaria Vaccine Yields Positive Results PDF Print E-mail
Thursday, 08 September 2011 16:35

Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published today in the online issue of Science.

Read more...
 
Custirsen For Treatment Of Prostate Cancer - Publication Of Phase II Clinical And Pre-Clinical Data Announced PDF Print E-mail
Thursday, 08 September 2011 16:32
The September issue of the journals Clinical Cancer Research and Cancer Researchpublished OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announcement of new data from its Phase II clinical and a pre-clinical study of custirsen (OGX-011/TV-1011), a drug that inhibits the production of clusterin, which is a protein commonly over-produced in cancer cells and a cause of treatment failure. 
Read more...
 
TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes PDF Print E-mail
Wednesday, 07 September 2011 01:39

TWi Biotechnology, Inc. announces the successful patient recruitment for the multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 122